Information on the cost-effectiveness of immunotherapy PD-L1 is required by decisionmakers in the health care system to determine the value of these novel treatment in extensive-stage SCLC in the world, for example NICE had already released Technology appraisal guidance [TA638] (https://www.nice.org.uk/guidance/ta638). This evidence concerns the gene CD274 and small cell lung carcinoma.